TRICIDA, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-06-13: Form 8-K; Period of report 2023-06-12; Description 1.03 Bankruptcy or Receivership; 3.03 Material Modification to Rights of Security Holders; 8.01 Other Events; Details 1.03.
- 2023-05-25: Form 8-K; Period of report 2023-05-22; Description 1.03 Bankruptcy or Receivership; 7.01 Regulation FD Disclosure; Details 1.03.
- 2023-04-26: Form 8-K; Period of report 2023-04-21; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2023-03-24: Form 8-K; Period of report 2023-03-21; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-06-13 | 8-K | 2023-06-12 | 1.03 Bankruptcy or Receivership; 3.03 Material Modification to Rights of Security Holders; 8.01 Other Events | 1.03 As previously disclosed, on January 11, 2023, Tricida, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the “Court”), thereby commencing a Chapter 11 case for the Company (Case No. 23-10024). 3.03 To the extent applicable to this item, the information set forth under Item 1.03 of this Current Report on Form 8-K is incorporated herein by reference. 8.01 The Company intends to file post-effective amendments to each of its Registration Statements on Form S-3, Form S-3ASR and Form S-8 and promptly file a Form 15 with the Securities and Exchange Commission, or the SEC, to deregister its securities under Section 12(g) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and suspend the Company’s reporting obligations under Sections 13(a) and 15(d) of the Exchange Act. | tcda-20230612.htm |
| 2023-05-25 | 8-K | 2023-05-22 | 1.03 Bankruptcy or Receivership; 7.01 Regulation FD Disclosure | 1.03 As previously disclosed, on January 11, 2023, Tricida, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the “Court”), thereby commencing a Chapter 11 case for the Company (Case No. 23-10024). 7.01 On May 22, 2023, the Company filed its monthly operating report (the “Monthly Operating Report”), with the Court for the reporting month ended April 30, 2023, a copy of which is attached hereto as Exhibit 99.1. | tcda-20230522.htm |
| 2023-04-26 | 8-K | 2023-04-21 | 7.01 Regulation FD Disclosure | 7.01 As previously reported, on January 11, 2023, Tricida, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the “Court”), thereby commencing a Chapter 11 case for the Company (Case No. 23-10024). | tcda-20230421.htm |
| 2023-03-24 | 8-K | 2023-03-21 | 7.01 Regulation FD Disclosure | 7.01 As previously reported, on January 11, 2023, Tricida, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the “Court”), thereby commencing a Chapter 11 case for the Company (Case No. 23-10024). | tcda-20230321.htm |
| 2023-03-21 | 8-K | 2023-03-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 In connection with the Chapter 11 Proceedings, on March 15, 2023, Tricida, Inc. (the “Company”) notified Dawn Parsell, previously a named executive officer who had been serving as the Company’s Executive Vice President, Clinical Development, that her employment with the Company would terminate, effective March 15, 2023. | tcda-20230315.htm |
| 2023-03-15 | 8-K | 2023-03-09 | 2.01 Completion of Acquisition or Disposition of Assets | 2.01 As previously disclosed, on January 11, 2023, Tricida, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing a Chapter 11 case for the Company (Case No. 23-10024) (the “Chapter 11 Proceedings”). | tcda-20230309.htm |
| 2023-02-24 | 8-K | 2023-02-21 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | tcda-20230221.htm |
| 2023-02-23 | 8-K | 2023-02-21 | 7.01 Regulation FD Disclosure | 7.01 As previously reported, on January 11, 2023, Tricida, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the “Court”), thereby commencing a Chapter 11 case for the Company (Case No. 23-10024). | tcda-20230221.htm |
| 2023-02-17 | 8-K | 2023-02-16 | 8.01 Other Events | 8.01 As previously reported, on January 11, 2023, Tricida, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the “Filing”), thereby commencing a Chapter 11 case for the Company (Case No. 23-10024)). | tcda-20230216.htm |
| 2023-01-27 | 8-K | 2023-01-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 23, 2023, Dr. David Bonita, a director of the board of directors (the “Board”) of Tricida, Inc. (the “Company”), notified the Company that he is resigning from the Company’s Board and all of the committees of the Board effective immediately. | tcda-20230123.htm |
| 2023-01-17 | 8-K | 2023-01-13 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 As previously reported, on January 11, 2023, Tricida, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the “Filing”), thereby commencing a Chapter 11 case for the Company (Case No. 23-10024)). | tcda-20230113.htm |
| 2023-01-12 | 8-K | 2023-01-09 | 1.01 Entry into a Material Definitive Agreement; 1.03 Bankruptcy or Receivership; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 Entry into a Material Definitive Agreement. 1.03 On January 11, 2023, the Company filed a voluntary petition for relief under chapter 11 (“Chapter 11”) of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (“Bankruptcy Court”) thereby commencing a Chapter 11 case for the Company (Case No. 23-10024). 2.04 As previously disclosed, on May 22, 2020, the Company entered into an indenture (the “Indenture”) with U.S. Bank National Association, as trustee (“US Bank”), relating to the Company’s Notes. 5.02 On December 23, 2022, the Board of Directors (the “Board”) of the Company approved an increase in the size of the Board from seven to eight members and on January 9, 2023, Thomas G. FitzGerald became a member of the Board. 5.03 Effective January 10, 2023, the Board adopted an Amendment to the Amended and Restated Bylaws of the Company (the “Bylaws Amendment”), a copy of which is filed herewith as Exhibit 3.1. | tcda-20230109.htm |
| 2023-01-04 | 8-K | 2022-12-28 | 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement | 2.04 As previously disclosed, on May 22, 2020, Tricida, Inc. (the “Company”) entered into an indenture (the “Indenture”) with U.S. Bank National Association, as trustee (“US Bank”), relating to the Company’s $200 million aggregate principal amount of 3.50% Convertible Senior Notes due 2027 (the “Notes”). | tcda-20221228.htm |
| 2022-12-22 | 8-K | 2022-12-19 | 8.01 Other Events | 8.01 As previously disclosed, on December 7, 2022, Tricida, Inc. (“Tricida”) received notice from Patheon Austria GmbH & Co KG (“Patheon”) alleging that Tricida was in material breach of the Manufacturing and Commercial Supply Agreement, effective October 4, 2019 (as amended by amendment no. 1 dated March 30, 2021, amendment no. 2 dated August 26, 2021, amendment no. 3 dated July 1, 2022 and amendment no. 4 dated September 15, 2022, collectively the “Agreement”) between Tricida and Patheon. | tcda-20221219.htm |
| 2022-12-12 | 8-K | 2022-12-07 | 1.02 Termination of a Material Definitive Agreement; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 1.02 On December 7, 2022, Tricida, Inc. (“Tricida”) received notice from Patheon Austria GmbH & Co KG (“Patheon”) alleging that Tricida was in material breach of the Manufacturing and Commercial Supply Agreement, effective October 4, 2019 (as amended by amendment no. 1 dated March 30, 2021, amendment no. 2 dated August 26, 2021, amendment no. 3 dated July 1, 2022, and amendment no. 4 dated September 15, 2022 collectively the “Agreement”) between Tricida and Patheon. 3.01 On December 8, 2022, Tricida received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company was not in compliance with Nasdaq’s Listing Rule 5450(b)(2)(C), as the market value of publicly held shares (the “MVPHS”) for the Company’s common stock had been below the minimum MVPHS requirement of $15,000,000 for 30 consecutive business days (the “MVPHS Requirement”). | tcda-20221207.htm |
| 2022-12-07 | 8-K | 2022-12-06 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On December 6, 2022, Tricida, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company was not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock had been below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). | tcda-20221206.htm |
| 2022-11-17 | 8-K | 2022-11-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On November 15, 2022, Tricida, Inc. (the “Company”) Company granted retention awards to employees of the Company, including certain of the Company’s named executive officers. 7.01 On November 17, 2022, the Company updated the slide deck presentation posted on its website to include additional information related to veverimer. | tcda-20221115.htm |
| 2022-11-14 | 8-K | 2022-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2022, Tricida, Inc. issued a press release announcing its financial results for its third quarter ended September 30, 2022. | tcda-20221114.htm |
| 2022-11-02 | 8-K | 2022-11-02 | 8.01 Other Events | 8.01 The press release is attached as Exhibit 99.1 and is incorporated into this Item 8.01 by reference. | tcda-20221102.htm |
| 2022-10-24 | 8-K | 2022-10-24 | 8.01 Other Events | 8.01 On October 24, 2022, Tricida, Inc. (the "Company") issued a press release providing top-line data from the VALOR-CKD renal outcomes clinical trial. | tcda-20221024.htm |
| 2022-10-20 | 8-K | 2022-10-19 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K with respect to the Loan Agreement is incorporated by reference into this Item 2.03. | tcda-20221019.htm |
| 2022-09-23 | 8-K | 2022-09-19 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | tcda-20220919.htm |
| 2022-08-08 | 8-K | 2022-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2022, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its second quarter ended June 30, 2022. | tcda-20220808.htm |
| 2022-08-04 | 8-K | 2022-07-30 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 Tricida expects the financial impact of this Amendment No. 3 to be a deferral until the fourth quarter of 2023 of approximately $8 million in costs from the prior manufacturing campaign that were budgeted to be spent under the Agreement. | tcda-20220730.htm |
| 2022-06-16 | 8-K | 2022-06-15 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 15, 2022, Tricida, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). | tcda-20220615.htm |
| 2022-05-19 | 8-K | 2022-05-19 | 8.01 Other Events | 8.01 On May 19, 2022, Tricida, Inc. issued a press release announcing that it is stopping its VALOR-CKD renal outcomes trial early for administrative reasons pursuant to the existing study protocol to allow for six months of financial runway following the reporting of top-line results, currently anticipated to occur in the fourth quarter of 2022. | tcda-20220519.htm |
| 2022-05-10 | 8-K | 2022-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2022, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its first quarter ended March 31, 2022. | tcda-20220510.htm |
| 2022-03-29 | 8-K | 2022-03-29 | 2.02 Results of Operations and Financial Condition | 2.02 On March 29, 2022, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its fourth quarter and full year ended December 31, 2021. | tcda-20220329.htm |
| 2022-03-02 | 8-K | 2022-03-02 | 8.01 Other Events | 8.01 On March 2, 2022, Tricida, Inc. issued a press release providing an update on the timing of top-line VALOR-CKD data based on conflict in Ukraine. | tcda-20220302.htm |
| 2022-01-10 | 8-K | 2022-01-07 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 As of December 31, 2021, Tricida, Inc., (the “Company”) had cash, cash equivalents and investments of approximately $150.6 million (unaudited). 7.01 On January 10, 2022, the Company intends to make a prerecorded presentation at the H.C. Wainwright BIOCONNECT Virtual Conference that provides a Company overview, business update and progress on the Company's key initiatives. | tcda-20220107.htm |
| 2021-11-15 | 8-K | 2021-11-12 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d243256d8k.htm |
| 2021-11-08 | 8-K | 2021-11-05 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On November 8, 2021, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its third quarter ended September 30, 2021. 5.02 On November 8, 2021, the Company announced that Wilhelm Stahl, Ph.D., the Company’s Executive Vice President, Chief Technology Officer, will transition to a part-time employment arrangement and will relinquish his day-to-day responsibilities overseeing the Company’s technical operations and supply chain functions, effective January 1, 2022. | tcda-20211105.htm |
| 2021-08-31 | 8-K | 2021-08-26 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 Tricida expects the financial impact of this Amendment No. 2 to be a net savings of at least $10 million against the amount that was otherwise budgeted to be spent under the Agreement between now and the end of 2022. | tcda-20210826.htm |
| 2021-08-16 | 8-K | 2021-08-12 | 8.01 Other Events | 8.01 On July 16, 2021, Tricida, Inc. (the “Company”) commenced a tender offer to exchange eligible stock options for replacement stock options with modified terms pursuant to the Offer to Exchange Eligible Options for New Options, dated July 16, 2021 (the “Exchange Offer”). | tcda-20210812.htm |
| 2021-08-09 | 8-K | 2021-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2021, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its second quarter ended June 30, 2021. | tcda-20210809.htm |
| 2021-06-15 | 8-K | 2021-06-10 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 10, 2021, Tricida, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). | tcda-20210610.htm |
| 2021-05-06 | 8-K | 2021-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 On May 6, 2021, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its first quarter ended March 31, 2021. | tcda-20210506.htm |
| 2021-04-01 | 8-K | 2021-03-30 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 As previously announced, the deferral of previously scheduled manufacturing campaigns, as set forth in the Amendment No. 1, is expected to result in a cash savings for Tricida, relative to its obligations under the current Agreement, of approximately $48.0 million through the end of 2022. | tcda-20210330.htm |
| 2021-03-16 | 8-K | 2021-03-12 | 1.02 Termination of a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.02 On March 12, 2021, Tricida, Inc. (the “Company”), as borrower, voluntarily prepaid in full all outstanding indebtedness, fees and other obligations and terminated all commitments and obligations (other than contingent obligations that expressly survive the termination thereof) under its Loan and Security Agreement, dated as of February 28, 2018 (as amended to date, the “Loan Agreement,”), between the Company and Hercules Capital, Inc., as administrative agent (in such capacity, the “Agent”), and each of the financial institutions party thereto as lenders (the “Lenders”). 7.01 The Company determined it was in its financial best interests to retire the borrowings under the Loan Agreement to eliminate the related interest expense as it optimizes its financial runway. | tcda-20210312.htm |
| 2021-03-02 | 8-K | 2021-02-26 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 The deferral of previously scheduled manufacturing campaigns, as agreed in the Binding Term Sheet, is expected to result in a cash savings for Tricida, relative to its obligations under the current Agreement, of approximately $48.0 million through the end of 2022. | tcda-20210226.htm |
| 2021-02-25 | 8-K | 2021-02-25 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On February 25, 2021, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its fourth quarter and full-year ended December 31, 2020. 8.01 On February 25, 2021, Tricida, Inc., issued a press release announcing that it had received an Appeal Denied Letter from the Office of New Drugs of the FDA to its Formal Dispute Resolution Request. | tcda-20210225.htm |
| 2021-02-22 | 8-K | 2021-02-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 16, 2021, the Company announced that Geoffrey Parker, Chief Financial Officer and Executive Vice President has been promoted to the newly created role of Chief Operating Officer, Chief Financial Officer and Executive Vice President. | tcda-20210216.htm |
| 2021-01-11 | 8-K/A | 2021-01-11 | 2.02 Results of Operations and Financial Condition | 2.02 In connection with the Company’s participation in the 39th Annual J.P. Morgan Healthcare Conference, the Company’s slide presentation referenced in Item 7.01 of the Original Form 8-K disclosed that the Company had approximately $332 million of cash, cash equivalents and investments (unaudited) as of December 31, 2020. | tcda-20210111.htm |
| 2021-01-11 | 8-K | 2021-01-06 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 On January 6, 2021, Tricida, Inc. (the “Company”), as borrower, Hercules Capital, Inc., as administrative agent (in such capacity, the “Agent”), and each of the financial institutions party thereto as lenders (the “Lenders”) entered into the Sixth Amendment to Loan and Security Agreement (“Sixth Amendment”) to amend certain terms of the Loan and Security Agreement, dated as of February 28, 2018 (as amended by that certain First Amendment to Loan and Security Agreement and First Amendment to Warrants dated as of April 10, 2018, that certain Second Amendment to Loan and Security Agreement, dated as of October 15, 2018, that certain Third Amendment to Loan and Security Agreement, dated as of March 27, 2019, that certain Fourth Amendment to Loan and Security Agreement, dated as of March 31, 2020, that certain Fifth Amendment to Loan and Security Agreement, dated as of May 18, 2020 and the Sixth Amendment, the “Loan Agreement”, and the term loans thereunder, the “Term Loan”) by and among the Company, the Agent and the Lenders. 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K with respect to the Amendment is incorporated by reference into this Item 2.03. | tcda-20210106.htm |
| 2021-01-11 | 8-K | 2021-01-11 | 7.01 Regulation FD Disclosure | 7.01 On January 13, 2021, Tricida, Inc. (the "Company") intends to make a slide presentation at the 39th Annual J.P. Morgan Healthcare Conference that provides a Company overview, business update and progress on the Company’s key initiatives. | tcda-20210111.htm |
| 2020-12-08 | 8-K | 2020-12-08 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On December 8, 2020, Tricida, Inc. (the "Company") intends to make a presentation to investors that provides updates on the veverimer development program, regulatory status and patent protection. 8.01 On December 8, 2020, the Company issued a press release announcing updates on the veverimer development program, regulatory status and new patent extension. | tcda-20201208.htm |
| 2020-12-04 | 8-K | 2020-12-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As part of Tricida, Inc.'s (the “Company's”) previously announced restructuring plan, on December 4, 2020 the Company announced that Marc Cobo will depart from his position as Senior Vice President, Finance and Chief Accounting Officer as of the close of business on December 4, 2020. | tcda-20201204.htm |
| 2020-11-09 | 8-K | 2020-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2020, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its third quarter ended September 30, 2020. | tcda-20201109.htm |
| 2020-10-29 | 8-K | 2020-10-25 | 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.05 On October 25, 2020, the Board of Directors of Tricida, Inc. (the “Company”) approved and on October 28, 2020 management began implementing, a restructuring plan to reduce operating costs and better align its workforce with the needs of its business following the completion of the Company’s End-of-Review Type A meeting with the U.S. Food and Drug Administration (“FDA”) on October 20, 2020. 5.02 On October 29, 2020, the Company announced that Susannah Cantrell, Ph.D. will depart from her position as Executive Vice President and Chief Commercial Officer as of the close of business on Friday October 30, 2020. 7.01 On October 29, 2020, the Company's management presented to investors using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.1 (the “Investor Presentation”) and is incorporated herein by reference. 8.01 On October 29, 2020, the Company issued a press release announcing that it had completed an End-of-Review Type A meeting with the FDA regarding its New Drug Application for veverimer on October 20, 2020. | tcda-20201025.htm |
| 2020-08-24 | 8-K | 2020-08-21 | 8.01 Other Events | 8.01 On August 24, 2020, Tricida, Inc. issued a press release announcing that it had received a complete response letter from the U.S. Food and Drug Administration regarding its New Drug Application for veverimer on August 21, 2020. | tcda-20200821.htm |
| 2020-08-05 | 8-K | 2020-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2020, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its second quarter ended June 30, 2020. | tcda-20200805.htm |
| 2020-07-15 | 8-K | 2020-07-14 | 8.01 Other Events | 8.01 Tricida, Inc. (the “Company”) submitted its New Drug Application (the “NDA”) for veverimer to the U.S. Food and Drug Administration (the “FDA”) through the Accelerated Approval Program in August 2019. | tcda-20200714.htm |
| 2020-06-30 | 8-K | 2020-06-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Tricida, Inc., (the "Company") announced that Marc Cobo has been appointed Senior Vice President, Finance and Chief Accounting Officer effective as of June 29, 2020. | tcda-20200629.htm |
| 2020-06-16 | 8-K | 2020-06-11 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.03 On June 11, 2020, Tricida, Inc. (the “Company”) held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”), at which stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to provide in Article IX, Section 9.1(b), that, unless a majority of the Company’s Board of Directors (the “Board”), acting on behalf of the Company, consents in writing to an alternative forum, the federal district courts of the United States of America will be the sole and exclusive forum for any action arising under the Securities Act of 1933. 5.07 At the Annual Meeting, the Company’s stockholders considered five proposals, each of which is described briefly below and in more detail in the Company’s definitive proxy statement filed on April 29, 2020. | tcda-20200611.htm |
| 2020-05-22 | 8-K | 2020-05-22 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference herein. 3.02 The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference herein. 8.01 On May 22, 2020, the Company issued a press release announcing the closing of the private placement of the Notes. | tcda-20200522.htm |
| 2020-05-20 | 8-K | 2020-05-19 | 8.01 Other Events | 8.01 On May 19, 2020, Tricida, Inc. (the "Company") issued press releases announcing the launch and pricing of a private offering of $175.0 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2027 (the "Notes"). | tcda-20200519.htm |
| 2020-05-19 | 8-K | 2020-05-18 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K with respect to the Amendment is incorporated by reference into this Item 2.03. | tcda-20200518.htm |
| 2020-05-07 | 8-K | 2020-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2020, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its first quarter ended March 31, 2020. | tcda-20200507.htm |
| 2020-04-15 | 8-K | 2020-04-14 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On April 15, 2020, Tricida, Inc. (the "Company") intends to make a slide presentation at the 19th Annual Needham Virtual Healthcare Conference. 8.01 In response to the 2019 novel coronavirus disease (COVID-19) pandemic, Tricida is working to ensure the continuity of its business operations as the situation with the COVID-19 pandemic continues to develop, while taking appropriate steps to ensure the safety of its clinical trial participants, investigators and employees. | tcda-20200414.htm |
| 2020-03-16 | 8-K | 2020-03-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 10, 2020, Steffen Pietzke tendered a notice of resignation to Tricida, Inc. (the “Company”) as Senior Vice President, Finance and Chief Accounting Officer with such resignation to be effective as of March 13, 2020. | tcda-20200310.htm |
| 2020-02-28 | 8-K | 2020-02-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 24, 2020, the Compensation Committee of the Board of Directors of Tricida, Inc. (the “Company”) authorized the amendment of the Company’s Executive Severance Plan (the “Plan”), which provides eligible participants, including each of the Company’s named executive officers, severance benefits in connection with certain qualifying terminations of employment. | tcda-20200224.htm |
| 2020-02-27 | 8-K | 2020-02-27 | 2.02 Results of Operations and Financial Condition | 2.02 On February 27, 2020, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its fourth quarter and full-year ended December 31, 2019. | tcda-20200227.htm |
| 2020-01-13 | 8-K | 2020-01-13 | 7.01 Regulation FD Disclosure | 7.01 On January 14, 2020, Tricida, Inc. (the "Company") intends to make a slide presentation at the 38th Annual J.P. Morgan Healthcare Conference that provides a company overview and business update. | jpmorganconference.htm |
| 2019-12-18 | 8-K | 2019-12-13 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 2.03 As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 28, 2019, Tricida, Inc. (the “Company”), as borrower, Hercules Capital, Inc., as administrative agent (in such capacity, the “Agent”), and each of the financial institutions party thereto as lenders, entered into the Third Amendment to Loan and Security Agreement (the “Amendment”), which amended certain terms of the Loan and Security Agreement, dated as of February 28, 2018 (as amended by that certain First Amendment to Loan and Security Agreement and First Amendment to Warrants, dated as of April 10, 2018, and that certain Second Amendment to Loan and Security Agreement, dated as of October 15, 2018, the “Prior Loan Agreement”; the Prior Loan Agreement as amended by the Amendment, the “Loan Agreement”), by and among the Company, the lenders party thereto and the Agent. | herculesfundingq42019.htm |
| 2019-11-14 | 8-K | 2019-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2019, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its third quarter ended September 30, 2019. | q320198k.htm |
| 2019-10-15 | 8-K | 2019-10-15 | 7.01 Regulation FD Disclosure | 7.01 On October 4, 2019, Tricida, Inc. (the “Company”) announced that it would host an Investor Day on Tuesday, October 15, 2019, from 8:30 a.m. to 11:30 a.m. | form8-kinvestorday.htm |
| 2019-10-10 | 8-K | 2019-10-04 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | form8-kpatheon.htm |
| 2019-09-04 | 8-K | 2019-09-04 | 8.01 Other Events | 8.01 On September 4, 2019, Tricida, Inc., issued a press release announcing that it has submitted a New Drug Application to the U.S. Food and Drug Administration under the Accelerated Approval Program for approval of veverimer (TRC101) for the treatment of metabolic acidosis in patients with chronic kidney disease. | a20190904-form8xkndasu.htm |
| 2019-08-19 | 8-K | 2019-08-19 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth under Item 1.01 of this Current Report on Form 8-K with respect to the Amendment is incorporated herein by reference. 8.01 On November 7, 2017, the Company entered into the Second Amendment with the Landlord. | thirdamendmenttolease8-k.htm |
| 2019-08-08 | 8-K | 2019-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2019, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its second quarter ended June 30, 2019. | q220198k.htm |
| 2019-06-25 | 8-K | 2019-06-25 | 7.01 Regulation FD Disclosure | 7.01 On June 25, 2019, Tricida, Inc. (the “Company”), published a press release which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | a20190620-form8xklance.htm |
| 2019-05-31 | 8-K | 2019-05-31 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The annual meeting of stockholders (the “Annual Meeting”) of Tricida, Inc. (the “Company”) was held on May 31, 2019. | a20190531-tricidax8xka.htm |
| 2019-05-08 | 8-K | 2019-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2019, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its first quarter ended March 31, 2019. | q120198k.htm |
| 2019-03-28 | 8-K | 2019-03-28 | 7.01 Regulation FD Disclosure | 7.01 On March 28, 2019, Tricida, Inc. (the "Company"), reported results from its blinded, randomized, placebo-controlled, 40-week extension trial, TRCA-301E. | trca-301e8xk.htm |
| 2019-03-28 | 8-K | 2019-03-27 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K with respect to the Amendment is incorporated by reference into this Item 2.03. | herculesthirdamendment8-k.htm |
| 2019-03-28 | 8-K | 2019-03-28 | 2.02 Results of Operations and Financial Condition | 2.02 On March 28, 2019, Tricida, Inc. (the "Company"), issued a press release announcing its financial results for its fourth quarter and full-year ended December 31, 2018. | q420188k.htm |
| 2019-02-22 | 8-K | 2019-02-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On February 20, 2019, the Compensation Committee of the Board of Directors (the “Board”) of Tricida, Inc. (the “Company”) approved the Tricida, Inc. Annual Incentive Plan (the “Plan”). 8.01 The Board has determined that, subject to any adjournments or postponements, the Company’s first annual meeting of stockholders (the “2019 Annual Meeting”) is expected to be held on Friday, May 31, 2019, commencing at 9:00 a.m. | form8-kxdraftx20190221annu.htm |
| 2019-01-07 | 8-K | 2019-01-07 | 7.01 Regulation FD Disclosure | 7.01 On January 9, 2019, Tricida, Inc. (the “Company”) intends to make a slide presentation at the 37th Annual J.P. Morgan Healthcare Conference that provides a company overview, business update and progress on the company’s key initiatives. | jpmorgan201901078-k.htm |
| 2019-01-03 | 8-K | 2018-12-28 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 2.03 As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on October 15, 2018 (the “October 2018 8-K”), Tricida, Inc. (the “Company”), as borrower, Hercules Capital, Inc., as administrative agent, and each of the financial institutions party thereto as lenders, entered into the Second Amendment to Loan and Security Agreement (the “Second Amendment”), which amended certain terms of the Loan and Security Agreement, dated as of February 28, 2018 (as amended, modified or supplemented from time to time including but not limited to that certain First Amendment to Loan and Security Agreement and First Amendment to Warrants dated as of April 10, 2018, together with the Second Amendment, the “Loan Agreement”). 3.02 The information set forth in Item 2.03 with respect to the Second Tranche Warrant is incorporated into this Item 3.02 by reference. | herculessecondtranche8-k.htm |
| 2018-11-08 | 8-K | 2018-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2018, Tricida, Inc., (the "Company") issued a press release announcing its financial results for its third quarter ended September 30, 2018. | q320188k.htm |
| 2018-10-18 | 8-K | 2018-10-18 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 is incorporated into this Item 2.03 by reference. | herculessecondamendment8-k.htm |
| 2018-08-08 | 8-K | 2018-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2018, Tricida, Inc., (the "Company") issued a press release announcing its financial results for its second quarter ended June 30, 2018. | q220188k.htm |
| 2018-07-02 | 8-K | 2018-07-02 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On July 2, 2018, Tricida, Inc., a Delaware corporation (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the completion of the Company’s initial public offering of shares of its common stock (the “Initial Public Offering”). | d629625d8k.htm |